Article Text

PDF
Variation in policies for the management of febrile neutropenia in United Kingdom Children’s Cancer Study Group centres
  1. Bob Phillips1,
  2. Karen Selwood2,
  3. Sheila M Lane3,
  4. Roderick Skinner4,
  5. Faith Gibson5,
  6. Julia C Chisholm6
  1. 1Paediatric Oncology Day Hospital, St James’s Hospital, Leeds, UK
  2. 2Royal Liverpool Children’s NHS Trust, Alder Hey, Liverpool, UK
  3. 3Bristol Royal Hospital for Children, Bristol, UK
  4. 4Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK
  5. 5Centre for Nursing and Allied Health Professions Research, Great Ormond Street Hospital for Children NHS Trust, London, UK
  6. 6Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London, UK
  1. Correspondence to:
    Dr Bob Phillips
    Paediatric Oncology Day Hospital, St James’s Hospital, Leeds LS9 7TF, UK; bob.phillips{at}doctors.org.uk

Abstract

Objective: To assess the variation in the current UK management strategies for the treatment of febrile neutropenia in childhood.

Design and setting: A postal survey of all 21 United Kingdom Children’s Cancer Study Group (UKCCSG) centres assessing and collating local policies, protocols or guidelines relating to the management of febrile neutropenia. Further direct contact was undertaken to clarify any uncertainties.

Results: All 21 centres provided information. The policies used to manage febrile neutropenia in the centres around the UK vary in almost every aspect of management. Definitions of fever ranged from a persistent temperature of >37.5°C to a single reading of >39°C. Neutropenia was inconsistently defined as an absolute neutrophil count of <1×109, <0.75×109 or <0.5×109. Choices of antibiotic approaches, empirical modifications and antistaphylococcal treatment were different in each protocol. The use of risk stratification was undertaken in 11 centres, with six using a policy of reduced intensity therapy in low risk cases. Empirical antifungal treatment was very poorly described and varied even more widely.

Conclusions: There was a great deal of variation in definitions and treatment of febrile neutropenia in the UKCCSG children’s cancer treatment centres. A degree of variation as a result of local microbiological differences is to be expected, but beyond this we should seek to standardise the core of our approach to defining fever and neutropenia, risk stratification and duration of empirical therapy in a way that maintains safety, minimises resource utilisation and maximises quality of life.

  • CVC, central venous catheter
  • FNP, febrile neutropenia
  • NICE, National Institute for Clinical Excellence
  • UKCCSG, United Kingdom Children’s Cancer Study Group

Statistics from Altmetric.com

Footnotes

  • Published Online First 6 February 2007

  • Funding: None.

  • Competing interests: None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Précis
    BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health
  • Atoms
    Howard Bauchner